Background Oxalis corniculata is a well-known medicinal plant used in folk medicine for the management of many diseases. The aim is to determine the physico-chemical properties, microscopic study, phytochemical properties, in-silico, in-vitro antioxidant and anticancer activity on human Hepatocarcinoma (Hep-G2) cell line of O. corniculata plant extract. Results Microscopical study reaveals that presence of pericyclic fibres, starch gains, trichomes etc, and phytochemical screening is carried to find out secondary metabolites. The molecular docking study concluded that some of the phytocompounds showed inhibition of epidermal growth factor receptor tyrosine kinase domain (PDB ID: 1M17) inhibitor. Furthermore, ADMET and drug likeness study hints some of phytocompounds may act as lead for anticancer drug discovery and development. Among selected phytocompounds, compound apigenin possesses − 7.90 kcal/mol as compared to standard drug doxorubicin possesses − 7.63 kcal/mol against the epidermal growth factor receptor tyrosine kinase. The plant extract shown antioxidant activities based on the different tests were performed. The hydroalcoholic plant extracts were found to be selectively cytotoxic in vitro to human Hepatocarcinoma (Hep-G2) cell line with IC50values 34.494 ± 0.42 µg/ml and EAF showed at IC50 value 30.245 ± 0.58 µg/ml of the cells were inhibited at the concentration of 50 µg/ml as compared with standard doxorubicin at IC50 value 24.8939 ± 0.25 µg/ml, respectively. Conclusion The present study concluded that O. corniculata possesses potential antioxidant and cytotoxic properties based upon the computer aided drug design models and in-vitro activity.

Background Heart Study has been operating for more than 40 years, and throughout that time it has found a number of risk variables that interact negatively to have an overall negative effect on cardiovascular disease (CVD) with an estimated 17.9 million deaths per year, CVD is the world's leading cause of death. Main body In the current study, we present spectrophotometric, chromatographic analysis and bioanalysis methods for qualitative and quantitative evaluation of 15 drugs, including small and large molecules, that the U.S. FDA approved between 2015 and June 2020 to treat CVD’s and in the current review work, they were presented. Short conclusion The review's conclusion is that spectroscopic, chromatographic and bioanalysis methods play important role in quality control and standardization of recently approved drugs from 2015 to 2020 for treating CVD’s in its bulk, pharmaceutical dosage form, synthetic mixture or human/rat plasma.